Sinopharm
1099.HK
#2042
Rank
S$9.56 B
Marketcap
$3.06
Share price
1.48%
Change (1 day)
-10.65%
Change (1 year)
The Sinopharm Group is a Chinese pharmaceutical company that researches, develops, produces, sells and markets pharmaceuticals and other health products.

P/E ratio for Sinopharm (1099.HK)

P/E ratio at the end of 2022: 50.1

According to Sinopharm's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 5.80732. At the end of 2022 the company had a P/E ratio of 50.1.

P/E ratio history for Sinopharm from 2009 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202250.117.28%
202142.7-17.02%
202051.5-45.23%
201994.0-13.26%
2018108-7.33%
2017117-11.43%
2016132-10.03%
2015147-3.44%
20141520.02%
2013152-18.75%
20121875.26%
2011178-47.83%
2010341-4.59%
2009357

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.